̶ Presentation to be webcast on www.exelixis.com
̶
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 6, 2018--
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at the Stifel 2018 Healthcare Conference
taking place November 13-14 in New York, NY. The Exelixis presentation
is scheduled for 10:15 AM EST / 7:15 AM PST on Tuesday, November 13,
2018.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the webcast. A
replay will also be available at the same location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our three
commercially available products, CABOMETYX® (cabozantinib),
COMETRIQ® (cabozantinib) and COTELLIC®
(cobimetinib), and have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to patients
worldwide. Supported by revenues from our marketed products and
collaborations, we are committed to prudently reinvesting in our
business to maximize the potential of our pipeline. We are supplementing
our existing therapeutic assets with targeted business development
activities and internal drug discovery – all to deliver the next
generation of Exelixis medicines and help patients recover stronger and
live longer. Exelixis is a member of Standard & Poor’s (S&P) MidCap 400
index, which measures the performance of profitable mid-sized companies.
For more information about Exelixis, please visit www.exelixis.com,
follow @ExelixisInc
on Twitter or like ExelixisInc
on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005146/en/
Source: Exelixis, Inc.
Investors Contact:
Exelixis, Inc.
Susan
Hubbard, 650-837-8194
EVP, Public Affairs and Investor
Relations
shubbard@exelixis.com
or
Media
Contact:
For Exelixis, Inc.
Hal Mackins,
415-994-0040
hal@torchcommunications.com